findmyKOL

Norman Gitlin, MD

Enriched profile

Medical Co-Director, Atlanta Gastroenterology Associates' Liver Center · Atlanta Gastroenterology Associates (Liver Center)

ORCIDNone on fileNPI
Region🇺🇸 Atlanta, GA · Southeast · United StatesSpecialtyGastroenterologyFocusViral Hepatitis (B/C)
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2023Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Norman Gitlin is Medical Co-Director, Atlanta Gastroenterology Associates' Liver Center at Atlanta Gastroenterology Associates (Liver Center). ClinicalTrials.gov lists 2 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 31 Aug 2026

Norman Gitlin, MD, is Medical Co-Director, Atlanta Gastroenterology Associates' Liver Center. The public record shows 146 publications with 9,273 citations (h-index 34), centered on Viral Hepatitis (B/C). It also documents an investigator role on 2 registered clinical trials, industry payments reported by 8 companies.

  • Top research focus: Viral Hepatitis (B/C)
  • 2 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 8 companies

Generated from the cited public record · current as of 31 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Viral Hepatitis (B/C)2 trialsHepatitis C2 trialsHepatitis C, Chronic2 trialsHepatitis, Chronic2 trials

Research focus

OpenAlex concept fingerprint
Viral Hepatitis (B/C)

Drugs & molecules

across trials, industry payments and publications
Rezdiffrageneric · ResmetiromClinical trialsIndustry payments38PublicationsEpclusageneric · Sofosbuvir / velpatasvirClinical trialsIndustry payments27PublicationsOcalivageneric · Obeticholic acidClinical trialsIndustry payments10Publications

Works with

trial sponsors and companies reporting payments
Madrigal PharmaceuticalsClinical trialsIndustry payments39Gilead Sciences, Inc.Clinical trialsIndustry payments34Intercept Pharmaceuticals, Inc.Clinical trialsIndustry payments10

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
34h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
8companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Public positions

sourced statements on record

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 31 Aug 2026

Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 31 Aug 2026

8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    64.3%
    Thyroid Hormone Receptor beta Agonist20%
    Rezdiffra100%
    Part D<11 patients
    Proton pump inhibitor17.4%
    Pantoprazole Sodium100%
    Part D<11 patients
  • Cardiovascular

    26.1%
    Loop diuretic14.8%
    Furosemide100%
    Part D<11 patients
    ACE inhibitor11.3%
    Lisinopril100%
    Part D<11 patients
  • Cancer & immunology

    9.6%
    Purine Antimetabolite9.6%
    Azathioprine100%
    Part D<11 patients

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 31 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    liverresources.org/directory-directory/listing/norman-gitlin-md-frcp-facp-facg

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →liverresources.org
  • Other

    mdatl.com/2014/10/doctor-receives-recognition-for-contributions-study-of-liver-disease

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdatl.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 31 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.